170 related articles for article (PubMed ID: 12014643)
1. Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI).
Pizzi C; Caraglia M; Cianciulli M; Fabbrocini A; Libroia A; Matano E; Contegiacomo A; Del Prete S; Abbruzzese A; Martignetti A; Tagliaferri P; Bianco AR
Anticancer Res; 2002; 22(2A):727-32. PubMed ID: 12014643
[TBL] [Abstract][Full Text] [Related]
2. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
4. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
7. [Minnesota multiphasic personality inventory of patients with allergic rhinitis].
Xi L; Zhang W; Zhao Y; Zhang L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Aug; 46(8):646-9. PubMed ID: 22169545
[TBL] [Abstract][Full Text] [Related]
8. Formal psychological testing in patients with paradoxical vocal fold dysfunction.
Husein OF; Husein TN; Gardner R; Chiang T; Larson DG; Obert K; Thompson J; Trudeau MD; Dell DM; Forrest LA
Laryngoscope; 2008 Apr; 118(4):740-7. PubMed ID: 18182970
[TBL] [Abstract][Full Text] [Related]
9. [Psychological examinations of the personality of patients with cardiac syndrome X].
Chodorowski Z; Majkowicz M; Waldman W; Ciećwierz D; Sein Anand J; Wnuk K; Ciechanowicz R
Przegl Lek; 2002; 59(4-5):281-5. PubMed ID: 12183989
[TBL] [Abstract][Full Text] [Related]
10. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
12. [High-dose Roncoleukin in patients with disseminated cutaneous melanoma: a phase 1 study].
Moiseenko VM; Novik AV; Orlova RV; Protsenko SA; Mikhaĭlichenko TD; Semenova AI; Tiukavina NV
Vopr Onkol; 2005; 51(5):546-9. PubMed ID: 16756008
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani GS
Anticancer Res; 2007; 27(4C):2985-8. PubMed ID: 17695482
[TBL] [Abstract][Full Text] [Related]
14. Influence of psychological factors on the response to clomipramine in hospitalized chronic low back pain patients. Preliminary data from a psychometric study.
Fouquet B; Goupille P; Jeannou J; Etienne T; Chalumeau F; Valat JP
Rev Rhum Engl Ed; 1997 Dec; 64(12):804-8. PubMed ID: 9476269
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of personality profiles in patients with chronic migraine.
Luconi R; Bartolini M; Taffi R; Vignini A; Mazzanti L; Provinciali L; Silvestrini M
Headache; 2007 Sep; 47(8):1118-24. PubMed ID: 17883516
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study.
Huland E; Burger A; Fleischer J; Fornara P; Hatzmann E; Heidenreich A; Heinzer H; Heynemann H; Hoffmann L; Hofmann R; Huland H; Kämpfer I; Kindler M; Kirchner H; Mehlhorn G; Moniak TH; Rebmann U; Roigas J; Schneider TH; Schnorr D; Schmitz HJ; Wenisch R; Varga Z; Vinke J
Folia Biol (Praha); 2003; 49(5):183-90. PubMed ID: 14680292
[TBL] [Abstract][Full Text] [Related]
19. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
20. Psychological status of patients with chronic urticaria.
Pasaoglu G; Bavbek S; Tugcu H; Abadoglu O; Misirligil Z
J Dermatol; 2006 Nov; 33(11):765-71. PubMed ID: 17073991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
